Head-to-head · Value Score
CoreAge Rx vs Direct Meds
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, Direct Meds a 79. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameDirect Meds
#44 · Grade B · Fair Price
Est. first month
$249/mo sublingual
Save ~87% vs brand-nameFDA warning letter. The FDA issued directmeds.com, Inc. dba DirectMeds a warning letter in September 2025. Check it on the FDA database.
Get this deal Full Direct Meds review →The verdict
CoreAge Rx takes it on Value Score, 93 to 79 — an est. $99/mo first month, with no teaser step-up baked in. Direct Meds isn't out of it: Needle-averse shoppers who want a sublingual option on both molecules and will do their own diligence on a newer, ambiguous operator.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | Direct Meds |
|---|---|---|
| Value Score | 93 (A+) | 79 (B) |
| Est. first month | $99/mo | $249/mo sublingual |
| Save vs brand-name | ~89% | ~87% |
| Semaglutide | $99/mo | $249/mo sublingual · $297/mo injectable |
| Tirzepatide | $149/mo | $299/mo sublingual · $399/mo injectable |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Not publicly listed |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Direct Meds
One of the few programs offering a sublingual GLP-1 alongside the injection, with the medication, nurse support and shipping bundled into a single monthly figure rather than billed beside it.
Why it's a deal
- Rare oral/sublingual route offered alongside injectable on both molecules
- All-inclusive pricing with no separate membership fee
- Both semaglutide and tirzepatide available, sublingual or injectable
The fine print
- The FDA issued this operator a warning letter in September 2025 — it is on the public FDA warning-letter database
- Compounded only (launched 2024) — not FDA-approved
- Bulk 6- and 12-month plans and new-customer discounts are advertised but not priced on the page, so the ongoing rate is the one to budget against
- Newer, ambiguous operator running multiple domains — do your own diligence
- States served are not publicly listed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to Direct Meds.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.